Virginia Commonwealth University

VCU Massey Cancer Center

Selected publications

Selected program member publications (2015)

Agarwal S, Bell CM, Rothbart SB, Moran RG. AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma Cells. J Biol Chem. 2015 Nov 13;290(46):27473-86. Epub 2015 Sep 21. PMCID: PMC4646000.

Agarwal S, Bell CM, Taylor SM, Moran RG. p53 Deletion or Hot-spot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb. Mol Cancer Res. 2015 Sep 18; PMCID: PMC4715954.

Bear HD, Tang G, Rastogi P, Geyer CE, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015 Sep;16(9):1037-48. Epub 2015 Aug 10.  PMCID: PMC4624323.

Das A, Durrant D, Mitchell C, Dent P, Batra SK, Kukreja RC. Sildenafil (Viagra) sensitizes prostate cancer cells to doxorubicin-mediated apoptosis through CD95. Oncotarget. 2015 Dec 24; [Epub ahead of print]. PMCID: PMC4826214.

Desai MA, Webb HD, Sinanan LM, Scarsdale JN, Walavalkar NM, Ginder GD, Williams DC. An intrinsically disordered region of methyl-CpG binding domain protein 2 (MBD2) recruits the histone deacetylase core of the NuRD complex. Nucleic Acids Res. 2015 Mar 31;43(6):3100-13. Epub 2015 Mar 9. PMCID: PMC4381075.

Dong C, Mao Y, Tempel W, Qin S, Li L, Loppnau P, Huang R, Min J. Structural basis for substrate recognition by the human N-terminal methyltransferase 1. Genes Dev. 2015 Nov 15;29(22):2343-8. Epub 2015 Nov 5. PMCID: PMC4691889.

Durrant DE, Das A, Dyer S, Tavallai S, Dent P, Kukreja RC. Targeted Inhibition of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Sensitizes Pancreatic Cancer Cells to Doxorubicin without Exacerbating Cardiac Toxicity. Mol Pharmacol. 2015 Sep;88(3):512-23. Epub 2015 Jun 22. PMCID: PMC4551046.

Elenewski JE, Hackett JC. Ab initio dynamics of the cytochrome P450 hydroxylation reaction. J Chem Phys. 2015 Feb 14;142(6):064307. PMCID: PMC4367892.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. Epub 2015 Mar 3. PMCID: PMC4371986.

Hata AN, Engelman JA, Faber AC. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics. Cancer Discov. 2015 May;5(5):475-87. Epub 2015 Apr 20. PMCID: PMC4727530.

Hilbert BJ, Morris BL, Ellis KC, Paulsen JL, Schiffer CA, Grossman SR, Royer WE. Structure-guided design of a high affinity inhibitor to human CtBP. ACS Chem Biol. 2015 Apr 17;10(4):1118-27. Epub 2015 Jan 30. PMCID: PMC4844192.

Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW. Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas. Leuk Lymphoma. 2016 Mar;57(3):635-43. Epub: 2015 Oct 12. PMCID: PMC4798896.

Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann MA, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala HM, Hogan K, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan DM, Landgren O, Grant S. A Phase 2 Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Mar 1;22(5):1067-75. Epub 2015 Oct 7. PMCID: PMC4775365.

Musayev FN, Zarate-Perez F, Bishop C, Burgner JW, Escalante CR. Structural Insights into the Assembly of the Adeno-associated Virus Type 2 Rep68 Protein on the Integration Site AAVS1. J Biol Chem. 2015 Nov 13;290(46):27487-99. Epub 2015 Sep 14. PMCID: PMC4646001.

Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE, Costantino JP, Wolmark N, Paik S. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol. 2015 Apr 20;33(12):1340-7. Epub 2015 Jan 5. PMCID: PMC4397278.

Remesh SG, Santosh V, Escalante CR. Structural Studies of IRF4 Reveal a Flexible Autoinhibitory Region and a Compact Linker Domain. J Biol Chem. 2015 Nov 13;290(46):27779-90. Epub 2015 Sep 24. PMCID: PMC4646024.

Richardson SL, Mao Y, Zhang G, Hanjra P, Peterson DL, Huang R. Kinetic mechanism of protein N-terminal methyltransferase 1. J Biol Chem. 2015 May 1;290(18):11601-10. Epub 2015 Mar 14. PMCID: PMC4416863.

Sarbeng EB, Liu Q, Tian X, Yang J, Li H, Wong JL, Zhou L, Liu Q. A functional DnaK dimer is essential for the efficient interaction with Hsp40 heat shock protein. J Biol Chem. 2015 Apr 3;290(14):8849-62. Epub 2015 Jan 28. PMCID: PMC4423677.

Sharon C, Baranwal S, Patel NJ, Rodriguez-Agudo D, Pandak WM, Majumdar AP, Krystal G, Patel BB. Inhibition of insulin-like growth factor receptor/AKT/mammalian target of rapamycin axis targets colorectal cancer stem cells by attenuating mevalonate-isoprenoid pathway in vitro and in vivo. Oncotarget. 2015 Jun 20;6(17):15332-47. PMCID: PMC4558155.

Sheldon JE, Dcona MM, Lyons CE, Hackett JC, Hartman MC. Photoswitchable anticancer activity via trans-cis isomerization of a combretastatin A-4 analog. Org Biomol Chem. 2016 Jan 7;14(1):40-9. Epub 2015 Oct 27. PMCID: PMC4681686.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Perez EA, Olson JA, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015 Nov 19;373(21):2005-14. Epub 2015 Sep 27. PMCID: PMC4701034.

Sperlazza J, Rahmani M, Beckta J, Aust M, Hawkins E, Wang SZ, Zu Zhu S, Podder S, Dumur C, Archer K, Grant S, Ginder GD. Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation. Blood. 2015 Sep 17;126(12):1462-72. Epub 2015 Aug 11. PMCID: PMC4573869.

White ER, Sun L, Ma Z, Beckta JM, Danzig BA, Hacker DE, Huie M, Williams DC, Edwards RA, Valerie K, Glover JN, Hartman MC. Peptide library approach to uncover phosphomimetic inhibitors of the BRCA1 C-terminal domain. ACS Chem Biol. 2015 May 15;10(5):1198-208. Epub 2015 Feb 5. PMCID: PMC4433557.

Yang J, Nune M, Zong Y, Zhou L, Liu Q. Close and Allosteric Opening of the Polypeptide-Binding Site in a Human Hsp70 Chaperone BiP. Structure. 2015 Dec 1;23(12):2191-203. Epub 2015 Nov 19. PMCID: PMC4680848.

Zhou L, Chen S, Zhang Y, Kmieciak M, Leng Y, Li L, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Rahmani M, Povirk L, Chalasani S, Berger AJ, Dai Y, Grant SThe NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR. Blood. 2016 Feb 5. pii: blood-2015-06-653717. [Epub ahead of print].